Vascular Biogenics Ltd.

As of March 28, 2019, Vascular Biogenics Ltd. is considered a poor investment due to its severe financial distress, indicated by a negative P/E ratio, low EV to EBITDA, and a year-to-date decline of 99.64%, making it overvalued compared to its peers.

As of March 28, 2019, Vascular Biogenics Ltd. is considered significantly overvalued with a valuation downgrade to "does not qualify," reflected by a concerning P/E ratio of -0.0001, an EV to EBITDA of 0.28, and a staggering ROE of -170.61%, alongside a year-to-date decline of 99.64% compared to a 2.44% gain in the S&P 500.

As of December 16, 2024, Vascular Biogenics Ltd. shows a mildly bearish trend due to daily moving averages indicating bearishness, while weekly and monthly indicators present mixed signals, leading to a cautious outlook.

As of March 2022, the management team of Vascular Biogenics Ltd. includes Dr. Bennett Shapiro (Non-Executive Independent Chairman), Prof. Dror Harats (CEO), and several Non-Executive Independent Directors: Ms. Ruth Alon, Prof. Ruth Arnon, Dr. Shmuel Ben Zvi, and Dr. Ron Cohen. They oversee the company's strategic direction and operations.

As of Jun 17, Vascular Biogenics Ltd. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -12.50 million over the latest four quarters. Shareholder's funds are 22.45 million, and total assets are 29.66 million as of Dec 22.